Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Europe
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Dantrium
2. Dantrolene
3. Dantrolene Sodium
4. Sodium, Dantrolene
1. Dantrolene Sodium
2. 14663-23-1
3. Tox21_500424
4. Ccg-221728
5. Ncgc00261109-01
6. Ac-25752
7. D 9175
Molecular Weight | 336.23 g/mol |
---|---|
Molecular Formula | C14H9N4NaO5 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 3 |
Exact Mass | 336.04706368 g/mol |
Monoisotopic Mass | 336.04706368 g/mol |
Topological Polar Surface Area | 110 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 530 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Dantrolene sodium |
Drug Label | The chemical formula of dantrolene sodium is hydrated 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-2, 4-imidazolidinedione sodium salt. It is an orange powder, slightly soluble in water, but due to its slightly acidic nature the solubility incre... |
Active Ingredient | Dantrolene sodium |
Dosage Form | Capsule |
Route | Oral |
Strength | 100mg; 25mg; 50mg |
Market Status | Prescription |
Company | Mikah Pharma; Impax Labs |
2 of 2 | |
---|---|
Drug Name | Dantrolene sodium |
Drug Label | The chemical formula of dantrolene sodium is hydrated 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-2, 4-imidazolidinedione sodium salt. It is an orange powder, slightly soluble in water, but due to its slightly acidic nature the solubility incre... |
Active Ingredient | Dantrolene sodium |
Dosage Form | Capsule |
Route | Oral |
Strength | 100mg; 25mg; 50mg |
Market Status | Prescription |
Company | Mikah Pharma; Impax Labs |
Muscle Relaxants, Central
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.
Lead Product(s): Dantrolene
Therapeutic Area: Musculoskeletal Brand Name: NPJ5008
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Lead Product(s) : Dantrolene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Norgine Receives Positive ChMP Opinion for NPJ5008 for Treating Malignant Hyperthermia
Details : NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.
Brand Name : NPJ5008
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2024
Details:
The accelerated share repurchase program will support Eagle's multiple anticipated and ongoing drug development activities which include RYANODEX franchise, anticipated near-term launch of vasopressin, and three potential oncology launches PEMFEXY, fulvestrant and SM-88.
Lead Product(s): Dantrolene
Therapeutic Area: Musculoskeletal Brand Name: Ryanodex
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: JPMorgan Chase Bank
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 24, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Partner/Sponsor/Collaborator : JPMorgan Chase Bank
Deal Size : $160.0 million
Deal Type : Financing
Details : The accelerated share repurchase program will support Eagle's multiple anticipated and ongoing drug development activities which include RYANODEX franchise, anticipated near-term launch of vasopressin, and three potential oncology launches PEMFEXY, fulve...
Brand Name : Ryanodex
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 24, 2020
Details:
The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimer’s disease. Eagle markets a formulation of dantrolene sodium but did not sponsor the study.
Lead Product(s): Dantrolene
Therapeutic Area: Neurology Brand Name: Ryanodex
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimer’s disease. Eagle markets a formulation of dantrolene sodium but did...
Brand Name : Ryanodex
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2020
Details:
Eagle is working to increase production of RYANODEX in advance of clinical results and to potentially shorten the supply chain lead time if necessary.
Lead Product(s): Dantrolene
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eagle Pharmaceuticals Announces Laboratory Test Results of RYANODEX Against Coronavirus SARS-CoV-2
Details : Eagle is working to increase production of RYANODEX in advance of clinical results and to potentially shorten the supply chain lead time if necessary.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2020
Details:
Eagle Pharmaceuticals and the University of Pennsylvania have entered a exclusive worldwide license agreement for the development of dantrolene sodium for treatment of Alzheimer’s disease.
Lead Product(s): Dantrolene
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Eagle Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 13, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Diseas...
Details : Eagle Pharmaceuticals and the University of Pennsylvania have entered a exclusive worldwide license agreement for the development of dantrolene sodium for treatment of Alzheimer’s disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 13, 2020
Details:
Under the terms of the agreement, NorthShore University HealthSystem will study Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.
Lead Product(s): Dantrolene
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Small molecule
Sponsor: Eagle Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 06, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, NorthShore University HealthSystem will study Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 06, 2020
RLD : No
TE Code :
Brand Name : DANTROLENE SODIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 20MG/VIAL
Approval Date : 2016-02-18
Application Number : 205239
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : RYANODEX
Dosage Form : FOR SUSPENSION;INTRAVENOUS
Dosage Strength : 250MG/VIAL
Approval Date : 2014-07-22
Application Number : 205579
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code : AB
Brand Name : DANTROLENE SODIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 25MG
Approval Date : 2005-10-24
Application Number : 76686
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : DANTROLENE SODIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Approval Date : 2005-10-24
Application Number : 76686
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AP
Brand Name : DANTROLENE SODIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 20MG/VIAL
Approval Date : 2017-06-19
Application Number : 204762
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AB
Brand Name : DANTROLENE SODIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Approval Date : 2005-03-01
Application Number : 76856
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : DANTROLENE SODIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 100MG
Approval Date : 2005-03-01
Application Number : 76856
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AP
Brand Name : REVONTO
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 20MG/VIAL
Approval Date : 2007-07-24
Application Number : 78378
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
Brand Name : DANTRIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 100MG
Approval Date : 1982-01-01
Application Number : 17443
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Brand Name : DANTRIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Approval Date : 1982-01-01
Application Number : 17443
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Canada
Brand Name : DANTROLENE SODIUM FOR INJECTION, USP
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 20MG/VIAL
Packaging :
Approval Date :
Application Number : 2529998
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : DANTRIUM CAPSULES
Dosage Form : CAPSULE
Dosage Strength : 25MG
Packaging : 100
Approval Date :
Application Number : 1997602
Regulatory Info :
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Canada
Brand Name : DANTRIUM INTRAVENOUS
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 20MG/VIAL
Packaging :
Approval Date :
Application Number : 1997572
Regulatory Info :
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Australia
Brand Name : Dantrium
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Dantrium iv
Dosage Form : INJ
Dosage Strength : 20mg/vial
Packaging : 1X1mg/vial
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Dantrium
Dosage Form : CAP
Dosage Strength : 25mg
Packaging : 50X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Dantrium iv
Dosage Form : INJ
Dosage Strength : 3000mg/vial
Packaging : 1X1mg/vial
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Application : Fillers, Diluents & Binders, Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Fillers, Diluents & Binders, Taste Masking
Dosage Form : Capsule, Granule / Pellet, Tablet, Injectable / Parenteral
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Thickeners and Stabilizers
Grade : Oral
Category : Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Thickeners and Stabilizers
Grade : Oral
Category : Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Injectable / Parenteral, Tablet
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Parenteral, Thickeners and Stabilizers
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2025-06-30
US Patent Number : 7758890
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 205579
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-06-30
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Dantrolene manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dantrolene, including repackagers and relabelers. The FDA regulates Dantrolene manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dantrolene API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dantrolene manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dantrolene supplier is an individual or a company that provides Dantrolene active pharmaceutical ingredient (API) or Dantrolene finished formulations upon request. The Dantrolene suppliers may include Dantrolene API manufacturers, exporters, distributors and traders.
click here to find a list of Dantrolene suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dantrolene DMF (Drug Master File) is a document detailing the whole manufacturing process of Dantrolene active pharmaceutical ingredient (API) in detail. Different forms of Dantrolene DMFs exist exist since differing nations have different regulations, such as Dantrolene USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dantrolene DMF submitted to regulatory agencies in the US is known as a USDMF. Dantrolene USDMF includes data on Dantrolene's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dantrolene USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dantrolene suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dantrolene as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dantrolene API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dantrolene as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dantrolene and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dantrolene NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dantrolene suppliers with NDC on PharmaCompass.
Dantrolene Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dantrolene GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dantrolene GMP manufacturer or Dantrolene GMP API supplier for your needs.
A Dantrolene CoA (Certificate of Analysis) is a formal document that attests to Dantrolene's compliance with Dantrolene specifications and serves as a tool for batch-level quality control.
Dantrolene CoA mostly includes findings from lab analyses of a specific batch. For each Dantrolene CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dantrolene may be tested according to a variety of international standards, such as European Pharmacopoeia (Dantrolene EP), Dantrolene JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dantrolene USP).
LOOKING FOR A SUPPLIER?